ClinicalTrials.gg
RecruitingNCT06671106SPAUpdated Mar 25, 2025

Efficacy of an Amine and Zinc Lactate - Containing Mouthrinse in the Home-based Treatment of Plaque-induced Gingivitis in Adolescents.

An interventional study of toothbrushing and flossing in Gingivitis, sponsored by Università degli Studi di Ferrara. Recruiting at 1 site in Italy. Open to participants aged 12 Years to 14 Years. Per ClinicalTrials.gov, last updated 2025-03-25.

Sponsored by Università degli Studi di Ferrara · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
12 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Gingivitis with a site in Italy — 9 open to participants now, 10 under way, 1 of them phase 3. Gingivitis · Italy.

Planned enrollment
4th of 28
150 · median 55
Started
2025
with 7 others
No phase
22 of 32
5 open now
Registered
21st of 32
by date

Among the 32 studies in Gingivitis with a site in Italy, this one is the 4th largest by planned enrollment of the 28 interventional ones that give a count, is one of 8 that started in 2025, is one of 22 with no phase, and was the 21st registered.

Gingivitis

635 studies on the registry are indexed under Gingivitis; 109 are open to participants now.

Browse Gingivitis studies →

Open to participants now

9 of the 32 studies in Gingivitis with a site in Italy are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 54 Gingivitis studies recruiting now, 16 (30%) set no upper age limit and 36 (67%) stop at 75 or younger; 11 take children under 18; 36 take healthy volunteers.

This study: 12 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Gingivitis with a site in Italy, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate if the adjunctive use of an amine and zinc lactate - containing mouthrinse may give significant benefits in the home-based treatment of plaque-induced gingivitis in adolescents. The study is based on the following hypothesis: the periodontal conditions of participants affected by gingivitis will significantly benefit from the implementation of the self-performed plaque control regimen (consisting of manual toothbrush and amine and zinc lactate toothpaste) with an amine and zinc lactate - containing mouthrinse. The benefit is expected to become manifest in terms of impact on clinical periodontal parameters, ecology of the subgingival environment, patient-reported outcomes and oral-health-related quality of life. In other words, gingivitis participants implementing their self-performed oral hygiene with the investigated mouthrinse are expected to assume a closer profile (based on the outcomes listed above) to periodontally healthy subjects when compared to gingivitis participants not using the investigated mouthrinse.

One hundred fifty participants (100 adolescents with gingivitis and 50 periodontally healthy adolescents) will be selected for the study. Gingivitis patients will be asked to participate in 5 observation intervals: screening visit, study baseline, and 3 follow-up visits (3 weeks, 3 months, 6 months), while periodontally healthy controls will conclude their participation in the study within the baseline visit.

According to the randomization list, at baseline gingivitis patients will receive one of the following home-based oral hygiene regimen:

  • test intervention (Gt group): manual toothbrush (meridol) and dental floss (meridol) associated with amine and zinc lactate - containing toothpaste (meridol Gum Protection) and amine and zinc lactate - containing mouthrinse (meridol Gum Protection);
  • control intervention (Gc group): manual toothbrush (meridol) and dental floss (meridol) associated with amine and zinc lactate - containing toothpaste (meridol Gum Protection); All periodontally healthy subjects will be assigned control intervention.

At baseline, both gingivitis patients and periodontally healthy subjects will undergo:

  • assessment of clinical periodontal parameters;
  • subgingival plaque sampling for microbiological analysis;
  • assessment of patient-reported outcomes (including oral-health related quality of life) using dedicated questionnaires; Gingivitis subjects will repeat the assessments at 3-week, 3-month, and 6-month follow-up visit.

The 6-month proportion of periodontally healthy participants in each gingivitis group (Gt and Gc) will be regarded as the primary outcome of the study. Changes in clinical parameters, subgingival microbial community profile, and scores related to patient-reported outcomes will be regarded as the secondary outcome measures.

03

Conditions studied

  • Gingivitis

Keywords

  • mouthrinse
  • plaque-induced gingivitis
  • adolescents
  • oral hygiene
  • amine lactate
  • zinc lactate
  • gingival inflammation
  • periodontal diseases
04

Who can participate

Ages eligible
12 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • systemically healthy;
  • eligible for oral care provision by Regional Health Service due to low socio-economic status;
  • at least 16 fully erupted teeth (excluding third molars);
  • diagnosed with plaque-induced gingivitis (G) or periodontal health (PH) according to the World Workshop case definitions (Trombelli et al. 2018, Chapple et al. 2018);
  • willing to participate in the study and capable to fully understand and comply with the study procedures (including questionnaire reading and filling).

Exclusion criteria

Exclusion Criteria:

  • pregnant or lactating;
  • current smoking;
  • motor and/or cognitive deficit impairing compliance with the study intervals or procedures;
  • legal guardian not willing to either allow for subject participation in the study or ensure adherence with the study procedures;
  • teeth with developmental defects (e.g., enamel pearls/projections);
  • untreated oral lesions, including dental caries or endodontic lesions;
  • fixed or removable orthodontic appliances or scheduled for orthodontic therapy with a timing not compatible with the experimental phase;
  • use of antibiotics in the previous 3 months;
  • use of medications that affect the size of the gingival tissues, such as phenytoin, sodium valproate, certain calcium channel-blocking drugs (e.g., nifedipine, verapamil, diltiazem, amlodipine, felodipine), and immune-regulating drugs (e.g., cyclosporine);
  • conditions (e.g., Sjögren's syndrome, anxiety, poorly controlled diabetes) or medications (e.g., antihistamines, decongestants, antidepressants) that are associated with hyposalivation.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Gingivitis - test intervention

    Gingivitis patients assigned to test intervention will use: manual toothbrush (meridol) and dental floss (meridol) associated with amine and zinc lactate - containing toothpaste (meridol Gum Protection) and amine and zinc lactate - containing mouthrinse (meridol Gum Protection)

    Other: toothbrushing · Other: flossing · Device: Toothpaste Product · Device: Mouthrinse

  • Active comparator
    Gingivitis - control intervention

    Gingivitis patients assigned to control intervention will use: manual toothbrush (meridol) and dental floss (meridol) associated with amine and zinc lactate - containing toothpaste (meridol Gum Protection)

    Other: toothbrushing · Other: flossing · Device: Toothpaste Product

  • Other
    Periodontal health - no treatment

    Periodontally healthy subjects will be compared for baseline assessments with gingivitis patients of the other two arms. However, periodontally subjects will conclude their participation in the study within the baseline visit after receiving devices and instructions related to the control intervention.

    Other: toothbrushing · Other: flossing · Device: Toothpaste Product

Interventions

  • Othertoothbrushing

    manual toothbrush (meridol)

  • Otherflossing

    dental floss (meridol)

  • DeviceToothpaste Product

    amine and zinc lactate - containing toothpaste (meridol Gum Protection)

  • DeviceMouthrinse

    amine and zinc lactate - containing mouthrinse (meridol Gum Protection)

06

What researchers measure

Primary outcomes

  1. 6-month proportion of periodontally healthy participants

    At 6 months, the proportion (range: 0%-100%) of cases of periodontal health (as diagnosed according to the case definition of the 2017 World Workshop) will be evaluated and compared between Gt and Gc groups.

    Time frame: 6 months

Secondary outcomes

  1. Gingival Index (GI)

    GI (without the BoP component) will be assessed on a scale from 0 (no clinically detectable inflammation) to 3 (severe inflammation with spontaneous bleeding) at the mesio-buccal aspects of 6 index teeth (i.e., 1.6, 2.1, 2.4, 3.6, 4.1, 4.4). Gt and Gc groups will be compared for the 3-week, 3-month and 6-month changes in Gi.

    Time frame: 3 weeks, 3 months, 6 months

  2. Plaque score

    Plaque score will be evaluated as present (0) or absent (1) at 6 sites (mesio-buccal, buccal, disto- buccal, mesio-lingual, lingual, disto-lingual) of each tooth. Gt and Gc groups will be compared for the 3-week, 3-month and 6-month changes in the full-mouth proportion of sites with plaque.

    Time frame: 3 weeks, 3 months, 6 months

  3. Bleeding on probing (BoP)

    BoP will be evaluated as present/absent using a UNC15 probe (Hu-Friedy Italy s.r.l., Milano, Italy) at 6 sites (mesio-buccal, buccal, disto-buccal, mesio- lingual, lingual, disto-lingual) of each tooth. Gt and Gc groups will be compared for the 3-week, 3-month and 6-month changes in the full-mouth prevalence of BoP (range: 0%-100%).

    Time frame: 3 weeks, 3 months, 6 months

  4. Probing depth (PD)

    PD will be measured in mm using a UNC15 probe (Hu-Friedy Italy s.r.l., Milano, Italy) at 6 sites (mesio-buccal, buccal, disto-buccal, mesio- lingual, lingual, disto-lingual) of each tooth. Gt and Gc groups will be compared for the 3-week, 3-month and 6-month changes in PD.

    Time frame: 3 weeks, 3 months, 6 months

  5. Clinical attachment level (CAL)

    CAL will be measured in mm using a UNC15 probe (Hu-Friedy Italy s.r.l., Milano, Italy) at 6 sites (mesio-buccal, buccal, disto-buccal, mesio- lingual, lingual, disto-lingual) of each tooth. Gt and Gc groups will be compared for the 3-week, 3-month and 6-month changes in CAL.

    Time frame: 3 weeks, 3 months, 6 months

  6. Plaque sampling and microbiological analysis

    Plaque sampling will be performed with sterile Mini Five Gracey curettes (Hu-Friedy Italy s.r.l., Milano, Italy) from the subgingival area at the mesio- buccal aspects of 6 index teeth (Manual of Procedures for Human Microbiome Project - Core Microbiome Sampling Protocol Version Number: 12.0; 29 Jul 2010). The microbial composition of each sample will be analyzed by a real-time quantitative PCR (qPCR) microarray, providing profiling of microorganisms usually found in dental plaque (Microbial DNA qPCR Array for Oral Disease) (Qiagen, Hilden, Germany). Array assays are designed using the 16S rRNA gene as the target gene and individual primers and hydrolysis-probe detection, increasing specificity of each assay. Amplification will be carried out in a Quant Studio 5 thermocycler (Thermo Fisher Scientific, Milan, Italy), providing simultaneous detection and quantification of 93 different microbial species, including putative and known periodontopathogens.

    Time frame: 3 weeks, 3 months, 6 months

  7. Patient satisfaction with the use of the oral hygiene regimen

    At 6 months, the participant will be asked to state his/her degree of satisfaction with the use of the oral hygiene regimen used during the experimental phase. Satisfaction will be classified as follows: 0- excellent; 1-good; 2- acceptable; 3- poor. The participant will also be asked about possible side effects and complaints related to the use of the assigned products. This evaluation will be performed without the presence of the examiners to enable the participant to give his/her honest opinion.

    Time frame: 6 months

  8. Oral-health related quality of life (OHrQoL)

    At baseline and 6 months, participants will be instructed to fill the Child Perceptions Questionnaire for 11- to 14 year-old Children (CPQ11-14). The questionnaire will be filled by the participant under the supervision of the examiner. The assessment is developed through 37 questions distributed in 4 sections, which refer to: oral symptoms, functional limitations, emotions related to the condition of the oral cavity, and what role this has in social relationships. Each question will be rated according to the following scale: never (0); once or twice (1); sometimes (2); often (3); every day or almost every day (4). The total score will be obtained as the algebraic sum of the single scores, and will range from 0 (indicating no impact of the oral health condition on the quality of life) to 148 (indicating maximum impact of the oral condition on the quality of life).

    Time frame: Baseline, 6 months

  9. Adverse events (AEs)

    Adverse events will be recorded on a dedicated form, and major adverse events will be immediately communicated to the Operative Unite of Legal Medicine, University - Hospital of Ferrara, Italy.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Operative Unit of Dentistry
    Ferrara, 44121, Italy
    Recruiting
08

References and documents

Publications

  • Montesani L, Montesani L, Mateo L, Daep C, Huber N, Isapour G, Zhang YP. Antibacterial and clinical effectiveness of a mouthwash with a novel active system of amine + zinc lactate + fluoride: a randomized controlled trial. Clin Oral Investig. 2024 Jan 13;28(1):90. doi: 10.1007/s00784-023-05487-0. PubMed 38217757 ↗
  • Trombelli L, Farina R, Silva CO, Tatakis DN. Plaque-induced gingivitis: Case definition and diagnostic considerations. J Clin Periodontol. 2018 Jun;45 Suppl 20:S44-S67. doi: 10.1111/jcpe.12939. PubMed 29926492 ↗

Individual participant data

Plan to share: No — Biological samples (subgingival plaque) will be analyzed at the Section of Microbiology, University of Ferrara, Italy. However, the analysis will be conducted in a blinded fashion (no information related to patient identity and observation interval will be provided for each sample to be analyzed).

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jul 2026, 18 months after the start.

Of 207 non-industry interventional studies with no phase under Gingivitis, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 17. This study's planned 18 months is above that.

Counting every sponsor, half of 260 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2024
First posted
Nov 4, 2024
StartActual
Jan 7, 2025
Primary completionEst.
Jul 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06671106
Lead sponsor
Università degli Studi di Ferrara
Collaborators
Consorzio Futuro in Ricerca
Responsible party
Leonardo Trombelli (Full professor, Università degli Studi di Ferrara) — Principal investigator
First posted
Nov 4, 2024
Start date
Jan 7, 2025
Primary completion
Jul 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 25, 2025

Study contacts

Leonardo Trombelli, Full Professor and Director
Contact
leonardo.trombelli@unife.it
+390532688507
Roberto Farina, Associate Professor
Contact
roberto.farina@unife.it
+390532688506

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion